Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs

Launched by INTERNATIONAL AGENCY FOR RESEARCH ON CANCER · Sep 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to screen for cervical cancer using advanced technology. The researchers are developing an artificial intelligence (AI) system that analyzes urine samples to check for a virus called high-risk human papillomavirus (hr-HPV), which can lead to cervical cancer. They will also use special images of the cervix captured with a high-quality camera to help identify any precancerous changes. The goal is to create a fast and affordable method for screening and deciding on treatments for women in low- and middle-income countries, starting with women in Zimbabwe.

To be eligible for this study, women need to be between 25 and 49 years old, have not been screened for cervical cancer in the past three years, and be willing to give their consent to participate. Participants can expect to provide urine samples and cervical images over the course of the study. The trial will involve analyzing these samples and images, comparing the new AI methods to current testing practices, and looking at the costs involved. This research aims to help eliminate cervical cancer globally and improve women's health in the target regions.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • No cervical screening during the previous 3 years
• • Between the ages of 25 and 49 years
• • Understands and signs a written informed consent form
• Exclusion Criteria:
• • Refusal to take part for any reason
• • Actively menstruating or pregnant
• • Treated earlier for cervical precancer or cancer